Leilei Tu
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Charge-flip nanoparticles loaded with TAK1 inhibitors inhibit retinal neovascularization.
Journal: Journal of nanobiotechnology
Published: October 07, 2025
Clofarabine Enhances the Transduction Efficiency of Recombinant AAV2 in the Retina.
Journal: Investigative ophthalmology & visual science
Published: May 28, 2025
An Integrative Multi-Omics Analysis Reveals MicroRNA-143 as a Potential Therapeutic to Attenuate Retinal Angiogenesis.
Journal: Nucleic acid therapeutics
Published: April 01, 2022
TAK1 blockade as a therapy for retinal neovascularization.
Journal: Pharmacological research
Published: March 23, 2022
TAK1 signaling is a potential therapeutic target for pathological angiogenesis.
Journal: Angiogenesis
Published: March 04, 2021
A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization.
Journal: Angiogenesis
Published: February 03, 2020
Utility of Self-Destructing CRISPR/Cas Constructs for Targeted Gene Editing in the Retina.
Journal: Human gene therapy
Published: August 03, 2019
Gene therapy for diabetic retinopathy: Are we ready to make the leap from bench to bedside?
Journal: Pharmacology & therapeutics
Published: January 31, 2017
AAV-Mediated CRISPR/Cas Gene Editing of Retinal Cells In Vivo.
Journal: Investigative ophthalmology & visual science
Published: July 02, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026